What the buyer needs
AI summaryThe buyer requires a vendor to provide a simulation-augmented, real-time platform. The requested scope involves establishing platform-level processes, documents, data structures, decision rules, and a governance framework to support concurrent intervention arms under a common operational structure. Vendors must perform the work offsite at their own office premises. Only USA organizations qualify as eligible bidders for this onshore opportunity. Vendors must submit a Scope of Work document following a specific template that details technical tasks, subtasks, milestones, deliverables, research involvement, and task timelines ranging from Month 1 through 60. The buyer is currently looking for proposals to establish the budget.
Scope of work
- Provide a simulation-augmented, real-time platform
- Support multiple simultaneous interventions under a common operational structure
- Establish platform-level processes, documents, data structures, and decision rules
- Design regimen-, drug-, or arm-specific appendices and operational documents for efficient modification
- Establish a governance framework with defined roles, responsibilities, decision rights, and escalation pathways
Minimum qualifications
- Onshore (USA organization Only)
Documents to include with your response
- Scope of Work (SOW)
- Cost Workbook
Incumbent and award research
No incumbent history found for this requirement. The notice does not cite a current contract, and no earlier award from this buying office matches it.
Market context
Awards in the same category (Research and Development in Biotechnology (except Nanobiotechnology)). This is not this requirement's award history.
Recent similar awards: Department of Health and Human Services, NAICS 541714
| Vendor and award | Value | Ends |
|---|---|---|
| AMGEN USA INC75A50122C00065 · TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MA | $839.9M | Sep 29, 2032 |
| 4J THERAPEUTICS INC75A50124C00052 · THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF O | $63.1M | Mar 31, 2032 |
| BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL75A50124C00033 · THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFE | $122.5M | Mar 31, 2032 |
| SRI INTERNATIONAL75N93026F00002 · TO AWARD TASK ORDER C03 | $722.0K | Feb 19, 2032 |
| ADVANCED TECHNOLOGY INTERNATIONAL75A50123F61002 · OT TASK ORDER 2 | $129.1M | Jan 31, 2032 |
Top vendors in this category: Department of Health and Human Services, NAICS 541714, since Oct 1, 2024
1,143 contract awards in this NAICS over the period.
- 1. ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)$336.6M
- 2. AMGEN USA INC$215.9M
- 3. START2 GROUP, INC.$194.3M
- 4. SHIONOGI INC$156.1M
- 5. MAPP BIOPHARMACEUTICAL, INC.$133.1M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.